Astria Therapeutics Inc Stock Price, News & Analysis

Astria Therapeutics (NASDAQ:ATXS), a biopharmaceutical company developing therapies for allergic and immunologic diseases, has granted inducement stock options to two new employees. The options allow for the purchase of 180,000 shares of common stock at an exercise price of $6.56 per share, matching the closing price on August 1, 2025.

The options were granted under Astria's 2022 Inducement Stock Incentive Plan and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, contingent on continued employment.

Astria Therapeutics (NASDAQ:ATXS) announced its participation in the 2025 US Hereditary Angioedema Association (HAEA) National Summit in Baltimore, Maryland from July 10-13, 2025. The company will present four posters focused on their drug candidate navenibart for Hereditary Angioedema (HAE) treatment.

The presentations include: a Phase 3 trial overview (ALPHA-ORBIT), combined safety and efficacy data from Phase 1b/2 and long-term trials, recruitment challenges in rare disease trials, and attack severity reduction data from the ALPHA-STAR Phase 1b/2 trial. The posters will be displayed on July 11 (8:30am-6:00pm ET) and July 12 (8:30am-1:30pm ET).

Astria Therapeutics (Nasdaq:ATXS), a biopharmaceutical company developing therapies for allergic and immunologic diseases, has granted stock options to six new employees under its 2022 Inducement Stock Incentive Plan. The options allow purchase of 119,860 shares at an exercise price of $5.43 per share, matching the closing price on July 1, 2025.

The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, contingent on continued employment.

Astria Therapeutics (NASDAQ: ATXS), a biopharmaceutical company specializing in allergic and immunologic disease therapies, announced its participation in the Oppenheimer Innovators in Immunology & Inflammation Summit. CEO Jill C. Milne, Ph.D., will join a panel discussion titled 'Advances in Dermatology: AD and CSU' on June 25, 2025, at 10:45am ET in New York, NY. The panel will focus on developments in atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) treatments.

Astria Therapeutics (NASDAQ:ATXS) reported positive initial results from the ALPHA-SOLAR long-term open-label trial of navenibart for hereditary angioedema (HAE). The trial demonstrated robust attack rate reductions, with a 95% mean reduction in the quarterly dosing arm (Q3M) and 86% in the semi-annual dosing arm (Q6M). Overall, patients showed a 92% mean and 97% median reduction in monthly attack rates. The drug achieved 50% attack-freedom over six months, with all 16 participants remaining in the trial. Navenibart displayed a favorable safety profile with no severe adverse events over 17 months of follow-up. The company's Phase 3 ALPHA-ORBIT trial is currently enrolling patients, evaluating both Q3M and Q6M dosing regimens. These results support navenibart's potential as a market-leading HAE therapy with infrequent dosing options.

Astria Therapeutics announced its participation at the European Academy of Allergy and Clinical Immunology Annual Congress in Glasgow from June 13-16, 2025. The company will present four posters focusing on navenibart for Hereditary Angioedema (HAE) treatment and STAR-0310 for Atopic Dermatitis. Key presentations include combined safety and efficacy data from Phase 1b/2 and long-term trials, STAR-0310's differentiation mechanism, Phase 1b/2 trial results, and information about the global Phase 3 ALPHA-ORBIT trial. Notable speakers include Dr. William Yang, Dr. Nikolaos Biris, Dr. William Lumry, and Dr. Emel Aygören-Pürsün.

Astria Therapeutics (NASDAQ: ATXS), a biopharmaceutical company developing therapies for allergic and immunologic diseases, has granted stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The options allow purchase of 62,000 shares of common stock at an exercise price of $4.78, matching the closing price on June 2, 2025. These options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, contingent on continued employment. This grant complies with Nasdaq Listing Rule 5635(c)(4) for inducement awards to new employees.

Astria Therapeutics (NASDAQ: ATXS), a biopharmaceutical company specializing in allergic and immunologic disease therapies, has announced that CEO Jill C. Milne, Ph.D. will participate in a fireside chat at the Jefferies Global Healthcare Conference. The presentation is scheduled for June 4th at 1:25pm ET. The event will be accessible via webcast, with a replay available on the company's investor website for 30 days following the presentation.

Astria Therapeutics (NASDAQ: ATXS) has announced its upcoming presentation at the 14th C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary. The presentation, scheduled for May 31, 2025, at 2:45 PM CET, will be delivered by Dr. Marc A. Riedl, Professor of Medicine and Clinical Director of the U.S. HAEA Angioedema Center at UC San Diego.

The presentation will focus on safety and efficacy data from the Phase 1a and Phase 1b/2 trials of navenibart in treating Hereditary Angioedema (HAE). The session, titled "Navenibart for Hereditary Angioedema (HAE): Analysis of Safety, Pharmacokinetic, and Pharmacodynamic Data From Phase 1a and Phase 1b/2 ALPHA-STAR Trial," will take place at the Ensana Thermal Hotel Margitsziget.